AN2 THERAPEUTICS INC's ticker is and the CUSIP is 037326105. A total of 19 filers reported holding AN2 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $660,020 | +56.3% | 41,046 | -17.4% | 0.00% | – |
| Q2 2023 | $422,221 | -18.1% | 49,673 | -4.9% | 0.00% | – |
| Q1 2023 | $515,461 | +5.1% | 52,225 | +1.5% | 0.00% | – |
| Q4 2022 | $490,366 | -3.1% | 51,455 | +76.8% | 0.00% | – |
| Q3 2022 | $506,000 | +34.9% | 29,107 | -39.8% | 0.00% | – |
| Q2 2022 | $375,000 | +2105.9% | 48,367 | +4076.8% | 0.00% | – |
| Q1 2022 | $17,000 | – | 1,158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Monashee Investment Management LLC | 233,330 | $4,055,000 | 1.50% |
| RA Capital Management | 3,773,517 | $65,584,000 | 1.40% |
| BVF INC/IL | 1,616,665 | $28,098,000 | 1.16% |
| Avidity Partners Management LP | 742,630 | $12,907,000 | 0.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 716,538 | $12,453,000 | 0.25% |
| Alyeska Investment Group, L.P. | 105,718 | $1,837,000 | 0.02% |
| Woodline Partners LP | 76,145 | $1,323,000 | 0.02% |
| Citadel Advisors | 1,336,983 | $23,237,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 5,726 | $100,000 | 0.00% |
| CITIGROUP INC | 134,545 | $2,338,000 | 0.00% |